NCT01706965View on ClinicalTrials.gov

Kuvan in People With Schizophrenia and Schizoaffective Disorder

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Kuvan

20mg/kg using a daily dosing schedule. To increase tolerability, treatment will be initiated at 10mg/kg for the first week of the study. Given the short length of the trial, no dose adjustments will be made for changes in weight

DRUG

Multivitamin

Multi-vitamin will be used as an active control in this study. Will be dosed daily

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

lead

New York State Psychiatric Institute

OTHER

NCT01706965 - Kuvan in People With Schizophrenia and Schizoaffective Disorder | Biotech Hunter | Biotech Hunter